Researchers have launched a series of clinical trials in order to assess the efficacy of an immunotherapy treatment. This approach involves the application of personalized vaccines — produced from healthy and tumor cells from the patient him or herself — and designed to combat glioblastomas, one of the most aggressive and frequent malignant tumors.